TAG

compounding

12 articles tagged compounding.

Compounded Tirzepatide Shortage Rules in 2026: What Changed and What Stayed the Same

FDA removed tirzepatide from its shortage list in late 2024. Here is what that meant for compounded tirzepatide access heading into 2026, and what did not change.

September 30, 2026

trt

Compounded Testosterone vs. Commercial Formulations: What the Regulatory Pathway Actually Means

Compounded testosterone and commercial testosterone travel different regulatory paths. Here is what FDA oversight, 503A rules, and quality checks actually mean for TRT patients.

September 29, 2026

peptides

Are Compounded Peptides Legal? The FDA's Current Regulatory Posture Explained

A plain-language breakdown of the FDA's 2023-2026 compounded peptide rules, Category 2 substances, and what the agency's advisory review means for patients.

September 26, 2026

peptides

503A vs. 503B Pharmacies: Why the Compounding Pathway Determines Peptide Access

503A and 503B pharmacies follow different FDA rules, and that difference decides which peptides a clinician can legally prescribe. Here's what it means for patients.

September 26, 2026

peptides

PT-141: What the Research Says About Its Current FDA Regulatory Status

Is PT-141 FDA-approved? Learn how Vyleesi's 2019 approval differs from compounded PT-141, what the research shows, and how prescribing actually works.

September 26, 2026

glp-1

What Factors Into the Monthly Cost of Compounded GLP-1 Medications

Compounded GLP-1 pricing varies widely. Here's what actually drives the monthly cost, from pharmacy sourcing to clinical monitoring, and how to evaluate a quote.

September 17, 2026

glp-1

What Does "Compounded" Mean for GLP-1 Medications? A Plain-Language Guide

A plain-language breakdown of what compounded means for GLP-1 medications, how it differs from FDA-approved brand drugs, and the pharmacy pathway behind it.

September 15, 2026

peptides

Peptide Sourcing Red Flags: What Separates a 503A Pathway from Gray-Market Vendors

Learn the concrete differences between a 503A compounding pathway and gray-market peptide vendors, plus the red flags that signal unsafe sourcing.

September 1, 2026

tirzepatide

Compounded Tirzepatide vs. Mounjaro: Understanding the 503A Pathway

Compounded tirzepatide and brand-name Mounjaro differ in FDA status, sourcing, and oversight. Learn how the 503A pathway works before you evaluate options.

August 23, 2026

peptides

Compounded Peptide Cost Transparency: What to Ask Before You Order

Compounded peptide pricing varies widely by pharmacy and protocol. Here are the specific questions patients should ask before ordering, and why they matter.

August 10, 2026

glp-1

Compounded GLP-1s After the Shortage: What Current 503A Rules Mean for Access

The national GLP-1 shortage has ended. Here's what FDA's 503A rules actually allow now, who still qualifies for compounded access, and how to check your options.

August 4, 2026

glp-1

Compounded Semaglutide vs. Ozempic: What "Compounded" Actually Means

Compounded semaglutide is not Ozempic. Here's what compounding actually means, how it differs from FDA regulatory review, and what to ask before starting.

August 2, 2026